NVS vs PFE vs ABBV Stock Comparison

Novartis Ag, Pfizer and AbbVie Prices as of Nov 13, 2026 Peers: Industry group
1 more company in this comparison (ONC) Create a free account to keep reading and compare up to 10 companies.
NVS Novartis Ag
$160.55 +9.3% 1M +21.7% 1Y
Market cap
$310.90B
P/E
17.9x
Revenue (TTM)
—
Div. yield
–
Pharmaceuticals Healthcare
1 win
PFE Pfizer Inc
$28.90 -1.1% 1M +12.1% 1Y
Market cap
$164.42B
P/E
40.8x
Revenue (TTM)
$63.63B
Div. yield
0.06%
Pharmaceuticals Healthcare
3 wins
ABBV AbbVie Inc.
$295.14 +4.1% 1M +27.1% 1Y
Market cap
$520.63B
P/E
50.3x
Revenue (TTM)
$66.01B
Div. yield
–
Pharmaceuticals Healthcare
7 wins

Head to Head

11 decided of 12

AbbVie leads on 7 of the 12 questions below (AbbVie 7, Pfizer 3, Novartis Ag 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionNVSPFEABBVLeader
Larger companyMarket capitalisation $310.90B $164.42B $520.63B ABBV
Cheaper on earningsLower P/E, profitable companies only 17.9x 40.8x 50.3x NVS
Cheaper on forward earningsLower price / next fiscal year consensus EPS 17.1x 9.8x 22.0x PFE
Faster revenue growthRevenue growth, trailing twelve months — +1.3% +10.7% ABBV
More profitableNet margin, trailing twelve months — 6.3% 15.7% ABBV
Better return on capitalReturn on invested capital — 12.3% 24.3% ABBV
Less leveragedLower net debt / EBITDA — 1.9x 2.4x PFE
Higher dividend yieldTrailing dividend yield 0.00% 0.06% 0.00% –
Better 1-year returnPrice return, last 12 months +21.7% +12.1% +27.1% ABBV
Better 5-year returnAnnualised price return, 5 years +14.3%/yr -10.3%/yr +20.3%/yr ABBV
Less volatileAnnualised volatility, 1 year 27.8% 21.7% 25.3% PFE
Higher overall scoreMean of the five percentile scores vs peers — 68/100 70/100 ABBV

Percentile Scorecard

NVSPFEABBV

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisNVSPFEABBV
Valuation 96 #26 of 660 95 #37 of 660 90 #68 of 660
Growth – 37 #392 of 619 67 #204 of 619
Profitability – 92 #50 of 595 96 #23 of 595
Financial Health – 25 #516 of 683 15 #580 of 683
Shareholder Returns 79 #97 of 459 91 #44 of 459 81 #89 of 459
Overall – 68 70
  • NVS ranked among 695 companies in Pharmaceuticals and Biotechnology
  • PFE ranked among 695 companies in Pharmaceuticals and Biotechnology
  • ABBV ranked among 695 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodNVSPFEABBVSPY
1 month +9.3%-1.1%+4.1% -2.0%
3 months +6.4%+7.9%+18.3% -2.8%
6 months +8.4%+14.1%+40.3% +2.0%
Year to date +16.5%+16.1%+29.2% +10.6%
1 year +21.7%+12.1%+27.1% +12.2%
3 years +69.2%-1.2%+113.8% +68.1%
3 years, per year +19.2%-0.4%+28.8% +18.9%
5 years +94.6%-41.9%+152.3% +61.4%
5 years, per year +14.3%-10.3%+20.3% +10.1%
10 years +118.5%-11.3%+367.7% +248.5%
10 years, per year +8.1%-1.2%+16.7% +13.3%

Risk

MeasureNVSPFEABBVSPY
Volatility, 1Y 27.8%21.7%25.3% 13.6%
Downside volatility, 1Y 30.0%21.9%24.1% 13.9%
Beta vs S&P 500, 1Y 0.360.26-0.02 1.00
Return / volatility, 1Y 0.780.561.07 0.90
Max drawdown, 5Y -20.4%-64.8%-24.3% -25.4%
From 52-week high -4.8%-6.1%0.0% -3.2%
52-week high $168.62$30.79$295.14 $779.14
52-week low $124.36$23.67$197.38 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleNVSPFEABBV
P/E now vs peer median 17.9xmedian 17.0x 40.8xmedian 17.0x 50.5xmedian 17.0x
P/S now vs peer median 5.1xmedian 8.4x 2.6xmedian 8.4x 7.9xmedian 8.4x
EV/EBITDA now vs peer median —median 14.6x 8.2xmedian 14.6x 20.4xmedian 14.6x
P/FCF now vs peer median 14.3xmedian 19.0x 14.0xmedian 19.0x 27.6xmedian 19.0x
P/B now vs peer median —median 2.0x 1.8xmedian 2.0x -113.8xmedian 2.0x
PEG now vs peer median —median 0.43 -1.47median 0.43 3.03median 0.43

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsNVSPFEABBV
Revenue – $63.63B $66.01B
Gross profit – $46.69B $48.67B
Operating income – $19.40B $21.23B
Net income – $4.06B $10.35B
Free cash flow – $11.79B $18.87B
R&D – $11.52B $9.96B
EPS (diluted) – $0.70 $5.84
Cash & equivalents $400.00M $1.82B $10.77B
Total debt – $62.67B $80.90B
Shares (diluted) 1.96B 5.75B 1.77B
Enterprise value $284.14B $111.77B $488.64B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricNVSPFEABBV
P/E 17.9x 40.8x 50.5x
P/FCF 14.3x 14.0x 27.6x
P/Operating cash flow – 11.6x 26.0x
P/S 5.1x 2.6x 7.9x
P/B – 1.8x -113.8x
P/Tangible book – 3.8x -8.5x
EV/EBITDA – 8.2x 20.4x
EV/EBIT – 11.0x 27.9x
EV/Revenue – 3.3x 9.0x
EV/FCF – 18.1x 31.4x
EV/Operating cash flow – 15.0x 29.5x
PEG (3Y EPS CAGR) – -1.47 3.03

Growth

14 metrics
MetricNVSPFEABBV
Revenue growth (1Y) – 1.3% 10.7%
Revenue CAGR (3Y) – -3.2% 6.2%
Gross profit growth (1Y) – 1.3% 17.0%
Gross profit CAGR (3Y) – 2.7% 10.3%
Operating income growth (1Y) – -4.3% 134.9%
Operating income CAGR (3Y) – 7.4% 12.1%
Net income growth (1Y) – -58.9% 331.9%
Net income CAGR (3Y) – -27.2% 16.6%
EPS growth (1Y) – -59.2% 333.1%
EPS CAGR (3Y) – -27.7% 16.6%
Operating cash flow growth (1Y) – 8.4% -3.7%
Operating cash flow CAGR (3Y) – 5.6% -7.7%
Free cash flow growth (1Y) – 13.6% -4.1%
Free cash flow CAGR (3Y) – 13.0% -8.6%

Profitability

14 metrics
MetricNVSPFEABBV
Gross margin – 73.4% 73.7%
EBITDA margin – 40.7% 43.9%
Operating margin – 30.5% 32.2%
Pretax margin – 6.7% 19.4%
Net margin – 6.3% 15.7%
FCF margin – 18.5% 28.6%
Operating cash flow margin – 22.3% 30.4%
Return on equity – 4.7% –
Return on assets – 2.0% 7.3%
Return on invested capital – 12.3% 24.3%
Return on capital employed – 11.3% 21.6%
Asset turnover – 0.3x 0.5x
Cash conversion (OCF / net income) – 3.5x 1.9x
Stock comp / revenue – 1.7% 1.4%

Financial Health

11 metrics
MetricNVSPFEABBV
Debt / assets – 30.6% 54.8%
Debt / equity – 0.7x -17.7x
Net debt / EBITDA – 1.9x 2.4x
Debt / FCF – 5.3x 4.3x
Liabilities / assets – 56.4% 103.1%
Equity / assets – 43.6% -3.1%
Interest coverage – – –
Current ratio – 1.4x 0.9x
Quick ratio – 0.9x 0.6x
Cash ratio – 0.4x 0.2x
Altman Z-score – 2.34 2.78

Shareholder Returns

7 metrics
MetricNVSPFEABBV
Dividend yield 3.0% 6.0% 2.3%
Net buyback yield – – 0.3%
Shareholder yield 3.0% 6.0% 2.6%
Payout ratio (earnings) – 241.2% –
Payout ratio (FCF) – 83.1% –
Dividend growth (1Y) – 0.9% –
Dividend CAGR (3Y) – 2.2% –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusNVSPFEABBV
Forward P/E 17.1xFY2026 9.8xFY2026 22.0xFY2026
EPS, next fiscal year $9.38FY2026 $2.95FY2026 $13.43FY2026
EPS growth, next FY +4.5%FY2026 -8.4%FY2026 +34.3%FY2026
EPS growth, the year after +0.9% -5.8% +24.3%
Revenue, next fiscal year $53.97BFY2026 $61.46BFY2026 $69.64BFY2026
Revenue growth, next FY -1.0%FY2026 -1.8%FY2026 +13.9%FY2026
Revenue growth, the year after +19.3% +4.0% -0.4%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersNVSPFEABBV
Held by institutions 7.0% 66.9% 74.9%
Institutions holding 1,610 2,842 4,183
Change in shares held, QoQ -6.0% +2.0% +2.6%
Institutions buying 662 1,327 2,206
Institutions selling 562 1,206 1,507
Buyers to sellers 1.18 1.10 1.46

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

NVSPFEABBV
NVS 1.00 0.49 0.52
PFE 0.49 1.00 0.37
ABBV 0.52 0.37 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, NVS, PFE and ABBV?

AbbVie (ABBV) is the largest by market capitalisation: Novartis Ag (NVS) $310.90B, Pfizer (PFE) $164.42B, AbbVie (ABBV) $520.63B.

Which stock is cheaper, NVS, PFE and ABBV?

Novartis Ag (NVS) trades on the lowest price-to-earnings ratio (Novartis Ag (NVS) 17.9x, Pfizer (PFE) 40.8x, AbbVie (ABBV) 50.3x). On next year's consensus earnings, Pfizer (PFE) is cheapest (Novartis Ag (NVS) 17.1x, Pfizer (PFE) 9.8x, AbbVie (ABBV) 22.0x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

AbbVie (ABBV) grew revenue fastest over the trailing twelve months: Pfizer (PFE) +1.3%, AbbVie (ABBV) +10.7%.

Which company is more profitable?

AbbVie (ABBV) has the highest net margin (Pfizer (PFE) 6.3%, AbbVie (ABBV) 15.7%). On return on invested capital, AbbVie (ABBV) leads (Pfizer (PFE) 12.3%, AbbVie (ABBV) 24.3%).

Which stock has performed better?

Over the past year AbbVie (ABBV) returned the most: Novartis Ag (NVS) +21.7%, Pfizer (PFE) +12.1%, AbbVie (ABBV) +27.1%. Over five years, AbbVie (ABBV) compounded fastest (Novartis Ag (NVS) +14.3%/yr, Pfizer (PFE) -10.3%/yr, AbbVie (ABBV) +20.3%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Novartis Ag (NVS) 0.00%, Pfizer (PFE) 0.06%, AbbVie (ABBV) 0.00%. Novartis Ag (NVS) and AbbVie (ABBV) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Pfizer (PFE) has been the steadiest (Novartis Ag (NVS) 27.8%, Pfizer (PFE) 21.7%, AbbVie (ABBV) 25.3%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, NVS, PFE and ABBV?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, AbbVie (ABBV) leads on 7. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.